Abstract: The present invention generally relates to immunogenic compositions comprising pan-coronavirus antigenic polypeptides and antibodies, and methods of use thereof for the treatment and prevention of coronavirus infection.

Abstract: The present invention generally relates to immunogenic compositions (e.g., vaccines and immunotherapies) that induce an immune response against Epstein Barr Virus (EBV)-associated antigens. The present invention also relates to methods of use thereof for the treatment and prevention of EBV infection, EBV-associated cancer, or a combination thereof. In various embodiments, the EBV antigen comprises BamHI-A rightward frame 1 (BARF1).

Abstract: Disclosed herein are nucleic acid molecules encoding a SARS-CoV-2 spike antigen. SARS-CoV-2 spike antigens, immunogenic compositions, and vaccines and their use in inducing immune responses and protecting against or treating a Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) infection in a subject.

Abstract: Nucleic acid molecules and compositions comprising one or more nucleic acid sequences that encode a consensus Marburgvirus filovirus glycoprotein immunogens. Immunomodulatory methods and methods of inducing an immune response against Marburgvirus are disclosed. Method of preventing infection by Marburgvirus and methods of treating individuals infected with Marburgvirus are disclosed. Consensus Marburgvirus filovirus glycoprotein immunogens are disclosed.

Abstract: Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided.

Abstract: Provided are compositions and methods for treating cancer using administration of certain volumes of CpG oligonucleotides (CpG ODN) and, optionally, administration of a checkpoint inhibitor such as an anti-PD-1 antibody, an anti-PD-L1 antibody, and/or an anti-CTLA-4 antibody. In preferred embodiments, the CpG ODN are selected based on their propensity to induce high amounts of interferon alpha (IFN-a) and T-cell activation relative to interleukin-10 (IL-10) and B-cell activation. In certain embodiments, the methods further include pretreatment with radiotherapy, to potentiate the combination immunotherapy.

Abstract: Provided herein is an immunogenic composition comprising a synthetic consensus antigen to chondroitin sulfate proteoglycan 4 (CSPG4) protein which is abundant in many cancers. Also disclosed herein is a method of treating a tumor associated pathology in a subject in need thereof, by administering the immunogenic composition to the subject.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets CTLA-4. The disclosure also provides a method of preventing and/or treating disease, such as cancer, in a subject using the composition of the invention.

Abstract: Disclosed herein are compositions comprising structurally modified DNA encoded antibodies (DMAbs), methods of structurally modifying DMAbs, and methods of using structurally modified DMAbs.

Abstract: A chemoenzymatic method of producing a polyhydroxybenzene includes contacting glucose with one or more biocatalysts under conditions suitable for the formation of D-glucodialdose; and thermally treating D-glucodialdose in the presence of a dehydration catalyst under conditions suitable for the formation of the polyhydroxybenzene. A chemoenzymatic method of producing 1,2,3,4-tetrahydroxybenzene includes contacting glucose with a mutated copper radical oxidase and catalase under conditions suitable for the formation of D-glucodialdose; and subjecting D-glucodialdose and a dehydration catalyst to temperatures ranging from about 40° C. to about 100° C. suitable for the formation of 1,2,3,4-tetrahydroxybenzene.

Abstract: Disclosed herein are compositions comprising a recombinant nucleic acid sequence encoding a bispecific anti-HIV natural killer engager, a fragment thereof, a variant thereof, or a combination thereof, and methods of use thereof.

Abstract: Disclosed herein are nucleic acid encoded Fc-modified antibodies and methods of use of the same for the treatment of diseases and disorders.

Abstract: Disclosed herein are antibodies to SARS-COV-2 antigens and recombinant nucleic acid sequences that encode the SARS-COV-2 antibodies. The disclosure also provides a method of preventing and/or treating a SARS-COV-2 infection or disease or disorder associated with SARS-COV-2 infection (e.g., COVID-19) in a subject using said compositions and methods.

Abstract: The present invention provides natural killer engagers specific for activating natural killer cells through binding to a Siglec, and nucleic acid molecules encoding the same, and methods for treating or preventing a disease or disorder using the same.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to an Ebola viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an Ebola virus infection in a subject using said composition and method of generation.

Abstract: Disclosed herein are compositions comprising a recombinant nucleic acid sequences encoding a bispecific anti-FSHR T cell engager as well as FSHR-specific CAR molecules, fragments thereof, variants thereof, combinations thereof, and methods of use thereof.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody to a Middle East Respiratory Syncytial Coronavirus (MERS-COV) viral antigen. Also disclosed herein is a method of generating a synthetic antibody in a subject by administering the composition to the subject. The disclosure also provides a method of preventing and/or treating an MERS-COV virus infection in a subject using said composition and method of generation.

Abstract: A molecular manufacturing process includes contacting a platform molecule with (i) a biocatalyst and (ii) a chemical catalyst under conditions suitable to produce a value-added chemical.

Abstract: Provided herein are sequences of Plasmodium spp. liver stage exported proteins as well as expression constructs expressing the sequences. Also provided herein are methods for generating an immune response against malaria using the expression constructs provided herein.

Abstract: Disclosed herein is a composition including a recombinant nucleic acid sequence that encodes an antibody or fragment thereof that targets PCSK9. The disclosure also provides a method of preventing and/or treating disease, such as cardiovascular disease or hypercholesterolemia, in a subject using the composition of the invention.